CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 953 enrolled
Drug / intervention
Durvalumab +Tremelimumab +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02542293
NCT02542293Phase 3Active
CompareCT.gov

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).

AstraZeneca·interventional·Posted Sep 7, 2015·Updated May 1, 2026

In Brief

A Phase 3 clinical trial evaluating Durvalumab +Tremelimumab, Paclitaxel + carboplatin, and 4 other interventions for Non Small Cell Lung Carcinoma NSCLC. Active but no longer recruiting, targeting 953 participants across 210 sites in 29 countries.

Detailed Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Carcinoma NSCLC
CountriesArgentina, Brazil, Bulgaria, Chile, China, Denmark, Finland, Greece, Hong Kong, India, Israel, Japan, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Singapore, South Korea, Sweden, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3Active
201620172018201920202021202220232024202520262027
First PostedSep 7, 2015
Enrollment StartNov 3, 2015
Primary CompletionSep 21, 2020
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 10.8 years ago

Interventions

Durvalumab +Tremelimumabbiological

Paclitaxel + carboplatindrug

Chemotherapy Agents

Gemcitabine + cisplatindrug

Chemotherapy Agents

Gemcitabine + carboplatindrug

Chemotherapy Agents

Pemetrexed + cisplatindrug

Chemotherapy Agent

Pemetrexed + carboplatindrug

Chemotherapy Agent